Table of Contents
Oxford Nanopore Technologies used its presentation at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 to set out a more focused commercial strategy for its nanopore sequencing platform, built around chosen applications, partners and 2030 financial targets. Chief executive officer Francis Van Parys, who joined in March from Danaher’s Radiometer, presented, with chief financial officer Nick Keher joining for questions.
Fewer, sharper bets
“We read native DNA and RNA directly, with protein analysis on the horizon, on the same platform,” Van Parys said. “This opens opportunities well beyond conventional sequencing.”
The strategy rests on four priorities the company published in August: customer-centric growth, focused innovation, disciplined execution and a high-performance culture. Oxford Nanopore puts its serviceable market at about $14 billion to $16 billion, a figure Van Parys said “doesn’t really mean anything in terms of what we can achieve.” Instead the company is concentrating on three markets: research, biopharma and selected clinical areas, with rare disease and tumor profiling among the clinical targets in its August presentation.
Build some, partner the rest
Van Parys said Oxford Nanopore would own the full solution where its technology is strongest, in research and biopharma, and partner where others bring validation, regulatory or market access. Examples include a GMP messenger RNA quality-control workflow launched with Lonza in May, which the companies said could cut testing from weeks to less than one day, and an agreement with MyOme to bring Oxford Nanopore sequencing into its Zenith rare disease platform, part of Natera’s portfolio.
“So we retain control where it matters, where we have our core capabilities, and we partner where it improves speed, reach, or returns,” Van Parys said.
Licensing is a third route. Oxford Nanopore has reported a cross-licensing agreement with an unnamed global diagnostics company worth a $20 million licensing fee in the second half of 2026 and $15 million of committed product purchases over 2027 and 2028, plus a low-to-mid-single-digit royalty for the life of the licensed patents.
New leadership
Van Parys pointed to recent hires, including the company’s first chief medical officer, Dr. Davide Manissero MD, who joined in August from Radiometer, and its first chief information officer, Andrew Watson. Sebastian Kronmueller, head of strategy and ventures at Philips, joins as chief business development officer on January 4, 2027.
Margins and 2030 targets
Oxford Nanopore has reported that consumables gross margin rose from about 64% in 2023 to about 75% in the first half of 2026, and devices and services margin from about 23% to about 34%. Van Parys said the company sees room to push consumables toward 80% and devices and services toward about 40%.
The company is targeting adjusted EBITDA break-even in 2027, positive free cash flow from 2028, and by 2030 revenue above $700 million with an adjusted EBITDA margin above 15%. Research made up 65.1% of revenue in the first half of 2026, and the company expects clinical and biopharma to grow fastest.
“But 2030 is not the end of our ambition,” Van Parys said. “We believe that we can build a $1 billion plus revenue business over time. We’re not putting a time frame towards that.”
Questions from the floor
Asked whether AI developers could become customers for Oxford Nanopore’s data, the company said the size of that opportunity “remains to be seen”. On protein sequencing, the company said work is progressing in two phases, beginning with peptide sequencing.
Asked what had gone wrong in the past, Van Parys said the platform “was developed for research applications”, and that “there was perhaps insufficient focus on where the technology made the greatest difference.” Clinical markets bring different rules, expectations, regulation and GMP rigor, and Van Parys said the company is now building the capabilities to meet them.
“And so now it’s time to deliver on a commercial opportunity and the science that was created,” Van Parys said.
About Oxford Nanopore
Oxford Nanopore Technologies plc (LSE: ONT) has developed a new generation of nanopore-based sensing technology used for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The company says its technology is used in more than 125 countries.
Onyx has previously covered last year’s Jefferies conference.
Sources: Oxford Nanopore presentation and Q&A, Jefferies Global Healthcare Conference, London, November 17, 2026; Oxford Nanopore investor conference announcement (November 4, 2026); Oxford Nanopore CEO appointment announcement (December 8, 2025); Oxford Nanopore half-year 2026 results and presentation (August 19, 2026); Oxford Nanopore leadership appointment announcements (May 21 and October 20, 2026); Oxford Nanopore and Lonza mRNA quality-control announcement (May 20, 2026)
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments